Iovance Biotherapeutics Inc to Provide Melanoma Regulatory and Clinical Updates Call Transcript
Good day, and thank you for standing by. Welcome to the Iovance Biotherapeutics Investor Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Sara Pellegrino, Vice President, Invest, Public Relations. Please go ahead.
Thank you, operator. Good morning, and thank you for joining us to discuss regulatory and clinical updates for lifileucel in metastatic melanoma.
During today's call, Dr. Fred Vogt, our Interim President and Chief Executive Officer, will highlight the positive FDA feedback on our potency assay matrix to support our planned BLA submission. Then Dr. Friedrich Finckenstein, our Chief Medical Officer, will further define our strategy for TIL combination therapy in front-line melanoma.
Following these updates, we will hold a Q&A session. Additional Iovance team members taking part in the Q&A include Jean-Marc Bellemin,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
